A progressive liver condition affects thousands of Americans, but early symptoms are often dismissed as everyday ailments.

Eli Lilly achieved the largest market capitalisation growth of 32.4% to $733bn in 2024, driven by strong demand for Mounjaro ...

I wasn't ill apart from some tiredness.” After being on the organ donor waiting list for four months, Mandy was matched with ...

Genfit SA ( ($GNFT) ) has shared an update. On January 30, 2025, GENFIT announced a significant non-dilutive royalty financing agreement with ...

Ironwood Pharmaceuticals, Inc.’s IRWD share price has dipped by 38.17%, which has investors questioning if this is right time ...

Advanz Pharma's bid to keep its Ocaliva treatment for rare liver disease primary biliary cholangitis (PBC) on the EU market has ended in failure. The European Commission revoked the conditional ...

Inc. (Nasdaq:THAR) ("" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced its participation in The Microcap ...

At the start of the year, there had been no new therapies for rare cholestatic liver disease primary biliary cholangitis (PBC) in the US for almost a decade. With the FDA approval of Gilead's ...

GENFIT signs royalty financing deal with HealthCare Royalty (HCRx) providing up to €185 million non-dilutive capital: €130 million upfront, with eligibility to receive up to €55 million in two ...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the ...

American Liver Foundation (ALF) is thrilled to announce the recipients of its prestigious 2024 Liver Scholar and Postdoctoral ...

Primary biliary cirrhosis (PBC ... and primary sclerosing cholangitis (PSC). The most frequent ANA patterns in PBC sera are the 'speckled' (Figure 1), the multiple nuclear dots (MND; Figure ...